Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan

Executive Summary

FDA wants more companies to adopt continuous manufacturing, which could expand the US manufacturing base.

Related Content

ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA
BIO Notebook Day 4: Gottlieb Seeks Early Engagement On Gene Therapy; Ireland’s Brexit Opportunities; AMAG’s Bremelanotide Strategy; Alzheimer’s ‘Learnings’
At Cross-Purposes? How Trump Budget's Part D Gap Discount Policy Aligns With New Law
FDA Should Drop Ban On Office Compounding, US House Members Say
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
FDA Commissioner Outlines Priorities For Tightening Oversight Of Drug Compounding Facilities
Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning
Drug Compounding Can't Be Justified By Price, FDA Says
FDA Making A Generic Case For Continuous Manufacturing
FDA Talks Up Continuous Manufacturing, Offers Assistance





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts